Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trials
- 67 Downloads
To characterize the pharmacokinetics of ombitasvir, paritaprevir, ritonavir, dasabuvir, and ribavirin in hepatitis C virus (HCV)-infected patients with chronic kidney disease stage 4 (CKD4) or end-stage renal disease (ESRD), including those on dialysis, in the open-label phase 3 RUBY-I and RUBY-II studies.
Patients (n = 18 CKD4, n = 68 ESRD) received ombitasvir/paritaprevir/ritonavir 25/150/100 mg once daily ± dasabuvir 250 mg twice daily ± ribavirin 200 mg once daily for 12 or 24 weeks. Intensive pharmacokinetic samples were collected from ten patients; sparse samples were collected from all patients. Arterial and venous samples were collected from three patients during hemodialysis. Area under the plasma concentration-time curve (AUC) was estimated using noncompartmental analyses for intensive data, and steady-state trough concentrations (Ctrough) were obtained from the sparse data. Pharmacokinetic results from RUBY-I and RUBY-II were compared empirically to historical data.
The AUC values of ombitasvir, paritaprevir, ritonavir, and dasabuvir were comparable between CKD4 and ESRD patients and were within the range of values observed in historical studies; dialysis had no effect on drug exposures. Ribavirin was extracted during hemodialysis but had similar exposures on dialysis and non-dialysis days. Individual steady-state Ctrough values for each drug overlapped between CKD4 and ESRD patients, and values in both groups were similar to historical values.
Plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir were not altered by renal impairment or dialysis, suggesting these agents can be administered to HCV-infected CKD4 or ESRD patients, including those on dialysis, without dose adjustment.
Clinicaltrials.gov identifiers: NCT02207088 (RUBY-I) and NCT02487199 (RUBY-II)
KeywordsHepatitis C virus End-stage renal disease Chronic kidney disease Renal impairment Ombitasvir/paritaprevir/ritonavir Dasabuvir
The authors thank the clinical sites, investigators, and AbbVie Drug Analysis. The authors thank Sonja Kemmis Causemaker, an employee of AbbVie, for her medical writing support.
Diana L. Shuster, Rajeev M. Menon, Bifeng Ding, Amit Khatri, Hong Li, Eric Cohen, Melissa Jewett, Daniel E. Cohen, and Jiuhong Zha contributed to the study design and analysis and interpretation of the data as well as the drafting and revising of the manuscript.
AbbVie provided financial support for the studies and participated in the design, study conduct, analysis, and interpretation of data as well as the writing, review, and approval of the manuscript.
Compliance with ethical standards
Conflict of interest
DLS, RMM, BD, AK, HL, EC, DEC, and JZ are current or former employees of AbbVie and may hold AbbVie stock and/or stock options. MJ is a contractor of AbbVie, employed by InVentiv Health.
The studies were conducted in accordance with International Council for Harmonization Good Clinical Practice guidelines and ethical principles that have their origin in the Declaration of Helsinki. The study protocols were approved by the independent ethics committees/institutional review boards.
Informed consent was obtained from all individual participants included in the studies.
- 4.Lucas GM, Jing Y, Sulkowski M, Abraham AG, Estrella MM, Atta MG, Fine DM, Klein MB, Silverberg MJ, Gill MJ, Moore RD, Gebo KA, Sterling TR, Butt AA, for the NA-ACCORD of the IeDEA (2013) Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals. J Infect Dis 208:1240–1249CrossRefGoogle Scholar
- 13.AASLD-IDSA (2017) Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus (unique populations/renal impairment). American Association for the Study of Liver Diseases (AASLD) and Infectious Diseases Society of America (IDSA) [online] [accessed on 01 Oct 2018] Available at: https://www.hcvguidelines.org/unique-populations/renal-impairment
- 14.Viekirax (ombitasvir, paritaprevir, and ritonavir) (2018) Summary of product characteristics. AbbVie Deutschland GmbH & Co. KG, GermanyGoogle Scholar
- 15.Exviera (dasabuvir) (2018) Summary of product characteristics. AbbVie Deutschland GmbH & Co. KG, GermanyGoogle Scholar
- 16.Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) (2018) [US package insert]. North Chicago, IL: AbbVie Inc.Google Scholar
- 17.Viekira XR (dasabuvir, ombitasvir, paritaprevir, ritonavir) (2018) [US package insert]. North Chicago, IL: AbbVie Inc.Google Scholar
- 18.Technivie (ombitasvir, paritaprevir, and ritonavir) (2018) [US Package Insert]. North Chicago, IL: AbbVie Inc.Google Scholar
- 22.Khatri A, Dutta S, Marbury T, Preston RA, Rodrigues L Jr, Wang H et al (2017) Pharmacokinetics and tolerability of anti-hepatitis C virus treatment with ombitasvir, paritaprevir, ritonavir, with or without dasabuvir, in subjects with renal impairment. Clin Pharmacokinet 56:153–163. https://doi.org/10.1007/s40262-016-0429-9:153-163 CrossRefPubMedGoogle Scholar
- 24.Pockros PJ, Reddy KR, Mantry PS, Cohen E, Bennett M, Sulkowski MS, Bernstein DE, Cohen DE, Shulman NS, Wang D, Khatri A, Abunimeh M, Podsadecki T, Lawitz E (2016) Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology 150:1590–1598CrossRefGoogle Scholar
- 25.Vierling JM, Lawitz E, Reddy KR, Cohen E, Kemmer N, Morelli G et al (2016) RUBY-I: safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin in adults with genotype 1 chronic hepatitis C virus (HCV) infection with severe renal impairment or end-stage renal disease. American Association for the Study of Liver Diseases (AASLD); 11–15 November 2016; BostonGoogle Scholar
- 26.Gane E, Sola R, Cohen E, Roberts S, George J, Skoien R et al. (2016) RUBY-II: efficacy and safety of a ribavirin-free ombitasvir/paritaprevir/ritonavir ± dasabuvir regimen in patients with severe renal impairment or end-stage renal disease and HCV genotype 1a or 4 infection. American Association for the Study of Liver Diseases (AASLD); 11–15 November 2016; BostonGoogle Scholar
- 27.Copegus (ribavirin) (2015) [US Package Insert]. South San Francisco, CA, USA: Genentech Inc.Google Scholar
- 29.Lalezari J, Sullivan JG, Varunok P, Galen E, Kowdley KV, Rustgi V, Aguilar H, Felizarta F, McGovern B, King M, Polepally AR, Cohen DE (2015) Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. J Hepatol 63:364–369CrossRefGoogle Scholar
- 30.Poordad F, Bennett M, Sepe TE, Cohen E, Reindollar RW, Everson G et al. (eds) (2015) QUARTZ-I: retreatment of HCV genotype 1 DAA-failures with ombitasvir/paritaprevir/r, dasabuvir, and sofosbuvir. American Association for the Study of Liver Diseases (AASLD); 13–17 November 2015; San FranciscoGoogle Scholar
- 31.Feld JJ, Moreno C, Trinh R, Tam E, Bourgeois S, Horsmans Y, Elkhashab M, Bernstein DE, Younes Z, Reindollar RW, Larsen L, Fu B, Howieson K, Polepally AR, Pangerl A, Shulman NS, Poordad F (2016) Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks. J Hepatol 64:301–307CrossRefGoogle Scholar
- 33.Shebley M, Liu J, Kavetskaia O, Sydor J, de Morais SM, Fischer V, Nijsen MJMA, Bow DAJ (2017) Mechanisms and predictions of drug-drug interactions of the hepatitis C virus three direct-acting antiviral regimen: paritaprevir/ritonavir, ombitasvir, and dasabuvir. Drug Metab Dispos 45:755–764CrossRefGoogle Scholar